[1] Siegel R L, Miller K D, Wagle N S, et al. Cancer statistics[J]. CA: A Cancer Journal for Clinicians, 2023, 73(1): 17-48.
[2] Yang J D, Hainaut P, Gores G J, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nature Reviews Gastroenterology & Hepatology, 2019, 16(10): 589-604.
[3] Sia D, Villanueva A, Friedman S L, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152(4): 745-761.
[4] Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition) [J]. Liver Cancer, 2020, 9(6): 682-720.
[5] Sun H C, Zhu X D. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: An overview[J]. Frontiers in Oncology, 2021, 11: 772195.
[6] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer Journal for Clinicians 2020, 70(1): 7-30.
[7] He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncology 2019, 5(7): 953-960.
[8] Li Q J, He M K, Chen H W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase Ⅲ trial[J]. Journal of Clinical Oncology, 2022, 40(2): 150-160.
[9] Breedis C, Young G. The blood supply of neoplasms in the liver[J]. American Journal of Pathology, 1954, 30: 969-977.
[10] Qin S, Bai Y, Lim H Y, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. Journal of Clinical Oncology, 2013, 31: 3501-3508.
[11] Lyu N, Lin Y, Kong Y, et al. FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67: 395-396.
[12] Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase Ⅲ, randomized clinical trial (LAUNCH)[J]. Journal of Clinical Oncology, 2023, 41: 117-127.
[13] Lai Z C, He M K, Bu X Y, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial[J]. European Journal of Cancer, 2022, 174: 68-77.
[14] Yoon S M, Ryoo B Y, Lee S J, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial[J]. JAMA Oncology, 2018, 4: 661-669.
[15] Zhang J, Zhang X, Mu H, et al. surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-pd-1 antibodies, and hepatic arterial infusion chemotherapy: A retrospective study[J]. Frontiers in Oncology, 2021, 11: 729764.
[16] Qu W F, Ding Z B, Qu X D, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: Real-world study[J]. BJS Open, 2022, 6(5): zrac114.
[17] Xue T, Le F, Chen R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: A large cohort study[J]. Medical Oncology, 2015, 32(3): 64.
[18] Huang Y H, Wu J C, Chen S C, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter[J]. Alimentary Pharmacology & Therapeutics, 2006, 23(1): 129-135.
[19] He M K, Le Y, Li Q J, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study[J]. Chinese Journal of Cancer, 2017, 36(1):, 83.
[20] Sun H C, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition) [J]. Hepatobiliary Surgery and Nutrition, 2022, 11(2): 227-252..
[21] Li B, Qiu J, Zheng Y, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma[J]. Annals of Surgery Open, 2021, 2(2): 1-7.
[22] Mei J, Lin W P, Shi F, et al. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy[J]. European Journal of Radiology, 2021, 142: 109890.
[23] Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: A propensity score-matching analysis[J]. Journal of Vascular and Interventional Radiology, 2021, 32(9): 1267-1276.e1.
[24] Mei J, Li S H, Li Q J, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. Journal of Hepatocellular Carcinoma, 2021, 8: 167-176.
[25] An C, Zuo M, Li W, et al. Infiltrative hepatocellular carcinoma: Transcatheter arterial chemoembolization versus hepatic arterial infusion chemotherapy[J]. Frontiers in Oncology, 2021, 11: 747496.
[26] Liang R B, Zhao Y, He M K, et al. Hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leu⁃covorin with or without sorafenib as initial treatment for advanced hepatocellular carcinoma[J]. Frontiers in Oncology, 2021, 11: 619461.
